TO: All Daavlin Employees and International Distributors
SUBJECT: SmartTouch Safety Features Compared to Straight Dosimetry
DEVICE TYPE/SERIAL NUMBERS AFFECTED: 3 Series Devices only
The reason for this bulletin is to inform the Daavlin Sales department and distributors of marketing techniques for Daavlin SmartTouch controlled equipment, especially the 3 Series PC and SP machines.
This pertains to 3 Series devices only.
The purpose is to inform Daavlin Sales employees and distributors of the safety advantages of Daavlin dosimetry controllers compared to competing machines with simple dosimetry controllers such as the NBC HOUVA III.
Recently it has been noticed that competing phototherapy manufacturers have attempted to downplay safety considerations and to merely compare all phototherapy dosimetry controllers as more or less equal, differing only in cost and appearance. Merely adding a touchscreen or a more sophisticated display to a simple dosimetry controller does not increase its safety profile and it is important to distinguish simple dosimetry from more advanced Daavlin controllers.
Since the 1993 introduction of the Daavlin UV2001 controller, Daavlin has taken great pains to produce controllers that, insomuch as possible, eliminate the potential for dosage errors, reduce physician liability, and promote accurate and effective treatment protocols. A comparison between the latest generation of Daavlin’s software, SmartTouch 2.01 and a simple dosimetry controller clearly shows the advantages:
2. Calculating the wrong percentage of increase between treatments.
3. Treating without enough time between treatments.
4. Using the wrong type of lamps in a combination machine (UVB instead of UVA or UVA instead of UVB).
5. Treating with too much time elapsed between treatments.
6. Having a poorly trained employee change a dose.
7. Confusing treatment protocols between patients.
8. Patient concerns about accidentally being over-treated
2. Automatically following scientifically supported protocols to ensure optimum patient outcomes.
3. Preventing any situation where a patient might be treated too soon after the last treatment.
4. Preventing a patient that has missed several treatments from getting treated with too high of a dose.
5. Never allowing a patient to be changed from one lamp type to another without authorization from a high level user and without starting at the beginning of the newly authorized protocol.
6. Automatically reminding even supervisory users with detailed warning messages if an attempt is made to change a dose.
7. Keeping detailed, printable, patient records, including actual treatments given, with dates, times, and protocol information.
8. Using a computer generated voice, in the patient’s native language to tell them how much time remains of their treatment, and to remind them to take appropriate eye and skin protective measures.